Predicted protein targets (top 14)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | ALDH1A1 | P00352 | 6/20 | 0.56 |
| ▸ | KDM4E | B2RXH2 | 4/20 | 0.56 |
| ▸ | LMNA | P02545 | 4/20 | 0.56 |
| ▸ | L3MBTL1 | Q9Y468 | 2/20 | 0.51 |
| ▸ | HPGD | P15428 | 2/20 | 0.51 |
| ▸ | ITGB3 | P05106 | 1/20 | 0.49 |
| ▸ | ITGA2 | P17301 | 1/20 | 0.49 |
| ▸ | MAPT | P10636 | 4/20 | 0.47 |
| ▸ | RAB9A | P51151 | 1/20 | 0.47 |
| ▸ | ALOX5 | P09917 | 1/20 | 0.47 |
| ▸ | KMT2A | Q03164 | 3/20 | 0.45 |
| ▸ | MEN1 | O00255 | 2/20 | 0.45 |
| ▸ | HTT | P42858 | 1/20 | 0.45 |
| ▸ | GAA | P10253 | 1/20 | 0.45 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL7197279 | 0.87 | ALDH1A1 (0.67) | ALDH1A1KDM4ELMNAL3MBTL1HPGD | |
| SCHEMBL350064 | 0.85 | ITGB3 (0.62) | ALDH1A1KDM4ELMNAITGB3ITGA2 | |
| SCHEMBL350063 | 0.85 | ITGB3 (0.62) | ALDH1A1KDM4ELMNAITGB3ITGA2 | |
| SCHEMBL3834631 | 0.82 | ALDH1A1 (0.54) | ALDH1A1KDM4ELMNAL3MBTL1HPGD | |
| SCHEMBL349307 | 0.81 | ITGB3 (0.58) | ALDH1A1LMNAITGB3ITGA2MAPT | |
| SCHEMBL349308 | 0.81 | ITGB3 (0.58) | ALDH1A1LMNAITGB3ITGA2MAPT | |
| SCHEMBL350069 | 0.80 | ITGB3 (0.49) | ALDH1A1KDM4ELMNAITGB3ITGA2 | |
| SCHEMBL10796469 | 0.79 | HTT (0.51) | ALDH1A1KDM4ELMNAITGB3ITGA2 | |
| SCHEMBL5352252 | 0.78 | ALDH1A1 (0.51) | ALDH1A1KDM4ELMNAL3MBTL1HPGD | |
| SCHEMBL7192146 | 0.78 | ALDH1A1 (0.61) | ALDH1A1KDM4ELMNAL3MBTL1HPGD |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-2252393-B1 | NOVEL CHIRAL SELECTORS AND STATIONARY PHASES FOR SEPARATING ENANTIOMER MIXTURES | EVONIK DEGUSSA GMBH (DE) | 2014-04-30 | — | — | EP | disclosed |
| US-20120015443-A1 | NOVEL CHIRAL SELECTORS AND STATIONARY PHASES FOR SEPARATING ENANTIOMER MIXTURES | EVONIK DEGUSSA GMBH (DE) | 2012-01-19 | — | — | US | disclosed |
| EP-2252393-A1 | NOVEL CHIRAL SELECTORS AND STATIONARY PHASES FOR SEPARATING ENANTIOMER MIXTURES | Evonik Degussa GmbH (DE) | 2010-11-24 | — | — | EP | disclosed |
| WO-2009112325-A1 | NOVEL CHIRAL SELECTORS AND STATIONARY PHASES FOR SEPARATING ENANTIOMER MIXTURES | EVONIK DEGUSSA GMBH (DE) | 2009-09-17 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20120015443-A1 | NOVEL CHIRAL SELECTORS AND STATIONARY PHASES FOR SEPARATING ENANTIOMER MIXTURES | BCAT2, BCAT1, SLC43A1 | ALDH1A1 1107/4885KDM4E 4413/4885LMNA 2351/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.